(Image: Shutterstock)
February 6, 2023 03:14 PM ESTUpdated 03:28 PM
Bioregnum
R&D

A long­time track­er on phar­ma R&D pro­duc­tiv­i­ty takes a post-pan­dem­ic plunge back to a bleak re­al­i­ty

John Carroll

Editor & Founder

So much for the “turn­around.”

The bio­phar­ma in­dus­try tossed the old play­book on R&D, broke every rule and bent every trend dur­ing the pan­dem­ic. Some …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times